Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
First Claim
Patent Images
1. A sustained release drug device adapted for implantation in or adjacent to the eye of a patient, the drug delivery device comprising:
- (i) an inner drug core comprising a carbonic anhydrase inhibitor;
(ii) a first coating on the surface of the drug core, that is substantially impermeable to the passage of the carbonic anhydrase inhibitor, having one or more openings therein which permit diffusion of the carbonic anhydrase inhibitor, and which is substantially insoluble and inert in body fluids and compatible with body tissues; and
(iii) one or more additional coatings that are permeable to the passage of the carbonic anhydrase inhibitor, and which are substantially insoluble and inert in body fluids and compatible with body tissues;
wherein the first and additional coatings are disposed about the inner drug core so as to produce, when implanted, a substantially constant rate of release of the carbonic anhydrase inhibitor from the device.
4 Assignments
0 Petitions
Accused Products
Abstract
The invention provides a device and method for treating and/or preventing raised intraocular pressure, such as that associated with glaucoma or the use of corticosteroids, with carbonic anhydrase inhibitors. The invention provides insertable sustained-release devices adapted to maintain a therapeutically effective concentration of one or more carbonic anhydrase inhibitors for an extended period of time, and a method of use thereof.
-
Citations
21 Claims
-
1. A sustained release drug device adapted for implantation in or adjacent to the eye of a patient, the drug delivery device comprising:
-
(i) an inner drug core comprising a carbonic anhydrase inhibitor;
(ii) a first coating on the surface of the drug core, that is substantially impermeable to the passage of the carbonic anhydrase inhibitor, having one or more openings therein which permit diffusion of the carbonic anhydrase inhibitor, and which is substantially insoluble and inert in body fluids and compatible with body tissues; and
(iii) one or more additional coatings that are permeable to the passage of the carbonic anhydrase inhibitor, and which are substantially insoluble and inert in body fluids and compatible with body tissues;
wherein the first and additional coatings are disposed about the inner drug core so as to produce, when implanted, a substantially constant rate of release of the carbonic anhydrase inhibitor from the device. - View Dependent Claims (3, 5, 7, 9, 10, 11, 12, 13)
-
-
2. A sustained release drug device adapted for implantation in or adjacent to the eye of a patient, the drug delivery device comprising:
-
(i) an inner drug core comprising a carbonic anhydrase inhibitor;
(ii) a first coating on the surface of the drug core, that is substantially impermeable to the passage of the carbonic anhydrase inhibitor, having one or more openings therein which permit diffusion of the carbonic anhydrase inhibitor, and which is substantially insoluble and inert in body fluids and compatible with body tissues; and
(iii) one or more additional coatings that are permeable to the passage of the carbonic anhydrase inhibitor, and which are substantially insoluble and inert in body fluids and compatible with body tissues;
wherein the impermeable coating has sufficient dimensional stability to be filled with a carbonic anhydrase inhibitor core without changing its shape.
-
- 4. A method for administering a carbonic anhydrase inhibitor to the ciliary body of an eye, the method comprising implanting a sustained-release device in or adjacent to the eye, whereby the device delivers the carbonic anhydrase inhibitor to the ciliary body of the eye, wherein the carbonic anhydrase inhibitor concentration in the ciliary body is maintained at a therapeutically effective concentration for a period of at least 30 days.
-
14. A sustained release drug delivery device adapted for insertion in or adjacent to the eye of a patient, the drug delivery device comprising:
-
(i) an inner drug core comprising at least one carbonic anhydrase inhibitor;
(ii) a coating layer on the surface of the drug core that is substantially impermeable to the passage of the at least one adrenergic agent, having one or more openings therein which permit diffusion of the adrenergic agent(s), and that is substantially insoluble and inert in body fluids and compatible with body tissues; and
wherein the coating is disposed about the inner drug core so as to produce, when inserted a substantially constant rate of release of the adrenergic agent(s) from the device. - View Dependent Claims (15, 16, 17)
-
-
18. A sustained release drug delivery device adapted for insertion in or adjacent to the eye of a patient, the drug delivery device comprising:
-
(i) an inner drug core comprising at least one carbonic anhydrase inhibitor;
(ii) a coating layer on the surface of the drug core that is partially or substantially permeable to the passage of the at least one carbonic anhydrase inhibitor, having one or more openings therein which aid diffusion of the at least one carbonic anhydrase inhibitor, and that is substantially insoluble and inert in body fluids and compatible with body tissues;
and wherein the coating is disposed about the inner drug core so as to produce, when inserted, a substantially constant rate of release of the at least one carbonic anhydrase inhibitor from the device. - View Dependent Claims (19, 20, 21)
-
Specification